$267 Million is the total value of Decheng Capital Management III (Cayman), LLC's 26 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPPRNCL | New | Alpine Immune Sciences, Inc. | $49,305,917 | – | 6,708,288 | +100.0% | 18.45% | – |
| ZNTL | Zentalis Pharmaceuticals Inc. | $36,747,102 | -7.0% | 1,824,583 | 0.0% | 13.75% | -4.0% | |
| RXDX | Prometheus Biosciences, Inc. | $27,500,000 | +86.4% | 250,000 | 0.0% | 10.29% | +92.4% | |
| Cue Health Inc. | $18,590,482 | -31.2% | 8,980,909 | 0.0% | 6.96% | -29.0% | ||
| RCUS | Arcus BioSciences, Inc. | $17,987,257 | -20.9% | 869,790 | 0.0% | 6.73% | -18.4% | |
| ILMN | Sell | Illumnia, Inc. | $16,349,690 | -34.2% | 80,859 | -37.9% | 6.12% | -32.0% |
| ALBO | Albireo Pharma, Inc. | $13,470,421 | +11.6% | 623,342 | 0.0% | 5.04% | +15.2% | |
| TXG | 10x Genomics, Inc. | $13,102,148 | +28.0% | 359,554 | 0.0% | 4.90% | +32.1% | |
| PACB | Pacific Biosciences of California, Inc. | $11,974,473 | +40.8% | 1,463,872 | 0.0% | 4.48% | +45.3% | |
| New | BeyondSpring Inc. | $9,321,309 | – | 4,958,143 | +100.0% | 3.49% | – | |
| HZNP | Horizon Therapeutics PLC | $8,978,820 | +83.9% | 78,900 | 0.0% | 3.36% | +89.8% | |
| TERN | Terns Pharmaceuticals, Inc. | $7,271,421 | +72.8% | 714,285 | 0.0% | 2.72% | +78.4% | |
| Aadi Bioscience, Inc. | $6,752,801 | -9.2% | 526,329 | 0.0% | 2.53% | -6.3% | ||
| MRSN | Mersana Therapeutics, Inc. | $5,299,010 | -13.3% | 904,268 | 0.0% | 1.98% | -10.5% | |
| ACET | Adicet Bio, Inc. | $5,185,200 | -37.1% | 580,000 | 0.0% | 1.94% | -35.1% | |
| EQ | Equillium Inc. | $4,892,039 | -50.5% | 4,447,308 | 0.0% | 1.83% | -48.8% | |
| Buy | Aura Biosciences, Inc. | $3,079,997 | -19.1% | 293,333 | +39.7% | 1.15% | -16.4% | |
| SGEN | Seagen Inc. | $2,957,529 | -6.1% | 23,014 | 0.0% | 1.11% | -3.1% | |
| ARGX | Argenx SE | $2,094,551 | +7.3% | 5,529 | 0.0% | 0.78% | +10.7% | |
| AtriCure Inc. | $2,052,974 | +13.5% | 46,259 | 0.0% | 0.77% | +17.1% | ||
| Apexigen, Inc. | $1,292,084 | -74.7% | 1,894,551 | 0.0% | 0.48% | -73.9% | ||
| GeneDx Holdings Corp. | $902,597 | -69.9% | 3,418,929 | 0.0% | 0.34% | -68.9% | ||
| SCYX | Scynexis Inc. | $866,666 | -35.0% | 555,555 | 0.0% | 0.32% | -32.9% | |
| NAUT | Nautilus Biotechnology, Inc. | $540,000 | -15.1% | 300,000 | 0.0% | 0.20% | -12.6% | |
| Owlet, Inc. | $502,295 | -47.7% | 898,400 | 0.0% | 0.19% | -46.0% | ||
| NBSE | NeuBase Therapeutics, Inc. | $190,200 | -51.8% | 1,000,000 | 0.0% | 0.07% | -50.3% | |
| BYSI | Exit | BeyondSpring Inc. | $0 | – | -4,958,143 | -100.0% | -1.78% | – |
| ALPN | Exit | Alpine Immune Sciences, Inc. | $0 | – | -6,708,288 | -100.0% | -17.51% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.